Compare GE Aerospace (GE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

GE trades at $353.73, up 0.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q1 2026 EPS of $1.86 versus $1.60 expected, driven by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margin improving to 18.98%. Analysts maintain a strong buy consensus with a $402.63 price target, reflecting optimism about order growth and backlog strength.

Outlook remains positive given earnings momentum and strategic investments in MRO and propulsion, though high valuation ratios (P/E 43.94) and debt levels pose risks. The stock offers upside to consensus targets but faces pressure from rising costs and competitive dynamics in aerospace and defense sectors.

Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.

Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.